Table 1. Disease activity parameters of patients grouped according to their biological (BT) or conventional (no BT) therapies.
| No BT (n = 21) | Anti-TNFα BT (n = 47) | Anti-CD20 BT (n = 10) | Anti-IL6R/Ig-CTLA4 BT (n = 13) | |||||
|---|---|---|---|---|---|---|---|---|
| Mean ± SD | CI (95%) | Mean ± SD | CI (95%) | Mean ± SD | CI (95%) | Mean ± SD | CI (95%) | |
| SW28 | 1.54 ± 2.32 | 0.51–2.58 | 0.91 ± 1.52 | 0.52–1.31 | 2.28 ± 3.45 | 0.29–4.28 | 1.2 ± 1.86 | 0.17–2.23 |
| TEN28 | 1.54 ± 3.02 | 0.21–2.88 | 0.98 ± 2.47 | 0.34–1.63 | 4.43 ± 8.07 | (-)0.23–9.09 | 1.71 ± 2.67 | 0.17–3.26 |
| DAS28 | 3.3 ± 1.1 | 2.8–3.8 | 3.4 ± 1.2 | 3.08–3.72 | 3.87 ± 1.51 | 2.99–4.74 | 2.54 ± 1.44 | 1.71–3.37 |
| PGA | 34.09 ± 22.37 | 23.91–44.28 | 39.60 ± 23.93 | 33.31–45.89 | 52.5 ± 21.73 | 39.95–65.04 | 42.33 ± 26.45 | 27.69–56.98 |
| HAQ | 0.89 ± 0.86 | 0.48–1.31 | 1.09 ± 0.71 | 0.90–1.28 | 1.59 ± 0.61 | 1.23–1.94 | 1.23 ± 0.76 | 0.79–1.68 |
| CRP (mg/L) | 8.67 ± 8.99 | 4.34–13.0 | 6.49 ± 8.8 | 4.05–8.94 | 9.4 ± 7.44 | 5.1–13.7 | 3.19 ± 3.16 | 1.44–4.94 |
| Platelets (× 10 9 cel/L) | 262.31 ± 107.29 | 214.74–309.88 | 262.03 ± 86.53 | 239.48–284.58 | 255.5 ± 90.2 | 203.42–307.58 | 222.53 ± 39.78 | 200.5–244.56 |
| % Erythrocytes | 40.26 ± 3.51 | 38.7–41.81 | 40.2 ± 4.3 | 39.08–41.32 | 41.6 ± 4.55 | 38.97–44.23 | 40.48 ± 4.36 | 37.72–43.96 |
| Haemoglobin (g/dL) | 13.55 ± 1.07 | 13.07–14.02 | 13.42 ± 1.48 | 13.03–13.80 | 13.68 ± 1.19 | 12.99–14.37 | 14.17 ± 1.62 | 13.28–15.07 |
| ESR (mm/h) | 30.14 ± 13.33 | 24.23–36.05 | 35.98 ± 25.35 | 29.38–42.59 | 26.64 ± 19.23 | 15.54–37.75 | 8.73 ± 8.28 | 4.15–13.32 |
n = number of patients; BT = biological therapy; CI = confidence interval; SD = standard deviation; SW28 = Swollen Joint Count; TEN28 = Tender Joint Count; DAS28 = Disease Activity Score; PGA = Patient Global Assessment; HAQ = Health Assessment Questionnaire; CRP = C-reactive protein; ESR = Erythrocyte Sedimentation Rate